For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Mazdutide is the world's first approved dual glucagon/GLP-1 receptor agonist. GLORY-1 Phase 3 (n=610, NEJM): 14.0% mean weight loss at 48 weeks with 6 mg dose. GLORY-2 (9 mg): 20.1% weight loss. DREAMS-1 and DREAMS-2 (Nature): superiority to dulaglutide in T2D. Liver fat reduction up to 80% (MRI-PDFF). Approved in China, not FDA-approved. All Phase 3 data from exclusively Chinese populations.
Mazdutide enters a crowded and rapidly evolving obesity pharmacotherapy landscape, but it does so with genuinely differentiated credentials: it is the world's first approved dual GCG/GLP-1 receptor agonist, with Phase 3 data published in the NEJM and Nature, and regulatory approval in China for both obesity and type 2 diabetes. The evidence is real and methodologically robust.
The critical caveat for most readers of The Signal is that the entire evidence base comes from Chinese-population trials. China uses different BMI thresholds, has a distinct obesity phenotype (higher body fat at lower BMI, different cardiometabolic risk profile), and Innovent's GLORY program enrolled participants at weight levels well below Western Phase 3 obesity trial norms. GLORY-1 participants had a mean baseline weight of 87.2 kg and mean BMI of 31.1 kg/m2: this is a leaner population than typical FDA-registration obesity trials. Whether the 11% to 14% weight loss seen in GLORY-1, or the 20% seen in GLORY-2 at 9 mg, translates to Western adults with higher baseline weights and different metabolic backgrounds is genuinely unknown.
Eli Lilly, which holds rights outside of China, is currently running a US Phase 2 trial (n=179) that will begin to answer this question. Phase 3 in Western populations has not been initiated. Realistic FDA approval is estimated at 2028 to 2029 at the earliest.
For the biohacker community looking for "the next semaglutide": mazdutide is approved and marketed in China as Xinermei. In the US, it exists only in Phase 2 investigation. Research chemical vendors sourcing product labeled as mazdutide are providing a compound without any Western regulatory framework or quality standards.
Mazdutide's origins trace to a natural hormone called oxyntomodulin, a 37-amino-acid proglucagon fragment secreted by intestinal L-cells in response to meals. Oxyntomodulin is an endogenous agonist of both GLP-1 and glucagon receptors simultaneously, and pharmacological administration of native oxyntomodulin reduces body weight in humans. The problem is that native oxyntomodulin has a very short half-life, making it impractical as a drug. Mazdutide is a mammalian oxyntomodulin analogue engineered for once-weekly subcutaneous dosing through fatty acid acylation and stabilizing amino acid modifications, an approach conceptually similar to how semaglutide extends the half-life of native GLP-1.
The compound was originally developed by Eli Lilly (designated LY3305677) and licensed to Innovent Biologics for the Chinese market in 2019. Innovent built out the entire Phase 2 and Phase 3 clinical program under the IBI362 designation. The Chinese development program is remarkably comprehensive for a not-yet-globally-approved drug: seven Phase 3 trials across obesity and T2D, multiple publications in top-tier journals, and two approved indications by the NMPA within 2025.
The glucagon receptor component is the defining differentiator from GLP-1 monotherapy. While GLP-1 receptor agonists primarily suppress appetite and slow gastric emptying, glucagon receptor activation increases energy expenditure through thermogenesis, promotes fatty acid oxidation in the liver, and has direct effects on hepatic fat metabolism. The scientific rationale for combining both is that appetite suppression (GLP-1) plus increased energy expenditure (glucagon) produces complementary and potentially additive weight loss, plus unique liver fat clearance properties that GLP-1 monotherapy does not share. This is the same mechanistic hypothesis driving survodutide and retatrutide.
Mazdutide simultaneously activates two receptors with complementary but distinct metabolic functions: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). This distinguishes it from all currently FDA-approved obesity and T2D drugs, which target GLP-1R alone (semaglutide, liraglutide) or GLP-1R plus GIP receptor (tirzepatide), but not GCGR.
GLP-1 receptor activation drives the mechanisms familiar from existing approved drugs: enhanced glucose-dependent insulin secretion, suppressed glucagon secretion, slowed gastric emptying, and central appetite suppression via hypothalamic and brainstem pathways.
Glucagon receptor activation is the novel component. Glucagon stimulates thermogenesis in brown adipose tissue, promotes lipolysis and fatty acid oxidation, and has direct hepatic effects that drive clearance of liver fat. In the context of mazdutide, the glucagon component is hypothesized to increase basal energy expenditure, add a complementary weight loss mechanism to the appetite-suppressive GLP-1 component, and produce the dramatic liver fat reductions observed in clinical trials (up to 80% reduction in MRI-PDFF).
The potential concern with glucagon receptor activation is hyperglycemia. Mazdutide's clinical data indicate this concern does not manifest at therapeutic doses, because the GLP-1 receptor co-activation simultaneously stimulates insulin secretion to offset any glucagon-mediated glucose rise. The net glycemic effect is neutral-to-beneficial, as confirmed by HbA1c reductions in T2D trials.
The increased heart rate observed in the high-dose Phase 1 trial (91.7% of mazdutide participants had a pulse rate increase of at least 10 bpm at 16 mg dose) is an important safety signal. At the Phase 3 doses (4 and 6 mg), the mean heart rate increase was 2.6 bpm, a much more modest finding.
In GLORY-1, the pivotal Phase 3 trial published in NEJM, 610 Chinese adults were randomized 1:1:1 to mazdutide 4 mg, 6 mg, or placebo for 48 weeks. Mean baseline weight was 87.2 kg (BMI 31.1 kg/m2).
At week 48, the mean percentage change from baseline was minus 11.00% with 4 mg, minus 14.01% with 6 mg, and 0.30% with placebo. Placebo-subtracted treatment differences were approximately minus 11.3% with 4 mg and minus 14.3% with 6 mg.
Responder analyses: 35.7% of 4 mg participants and 49.5% of 6 mg participants achieved at least 15% weight loss versus 2.0% with placebo (p less than 0.001). Multiple cardiometabolic secondary endpoints improved: waist circumference, blood pressure, lipids, HbA1c, liver enzymes, and serum uric acid. Liver fat content in participants with baseline MRI-PDFF at least 10% was reduced by 65.85% (4 mg), 80.24% (6 mg), and 5.27% (placebo). Adverse event-related discontinuation: 1.5% (4 mg), 0.5% (6 mg), 1.0% (placebo).
The GLORY-1 data are methodologically sound and published in the NEJM. The weight loss numbers are real: 14% at 48 weeks with 6 mg, with cardiometabolic benefits and a remarkably low discontinuation rate of 0.5%. The critical limitation for non-Chinese readers is population specificity: the entire dataset comes from Chinese adults at lower weights and under different BMI thresholds than Western registration trials. Harvard/BW and CU Anschutz NEJM editorialists specifically flagged this population distinction.
GLORY-2 evaluated mazdutide 9 mg in Chinese adults with obesity (BMI 30 kg/m2 or more) without T2D and demonstrated up to 20.1% mean body weight loss at 60 weeks, meeting all primary and key secondary endpoints. Liver fat reduction: 71.9% versus 5.1% with placebo. Adverse event-related discontinuation was 2.9% with 9 mg and 0% with placebo.
The Phase 2 trial of 9 mg (n=80, 24 weeks) showed placebo-adjusted weight reduction of 14.58% at week 24 (p less than 0.001). Nausea 50.0% vs. 0% (placebo), diarrhea 38.3% vs. 10.0%, vomiting 36.7% vs. 10.0%, predominantly mild to moderate.
The Phase 1 high-dose trial (n=32, predominantly US cohort, first Western population data) showed 20% to 21% mean weight loss at 20 weeks at 16 mg. Heart rate increased by at least 10 bpm in 91.7% of mazdutide participants at the 16 mg dose. No serious adverse events.
The 9 mg dose delivers approximately 14% to 20% weight loss depending on population and duration, placing it in the competitive range against semaglutide 2.4 mg and approaching the lower end of tirzepatide's efficacy range. The GI adverse event rates at 9 mg are higher than at 4 to 6 mg (50% nausea), consistent with dose-dependent tolerability. All data remain Chinese-population only for Phase 3.
DREAMS-1 and DREAMS-2 are two Phase 3 trials published back-to-back in Nature in December 2025. DREAMS-1 tested mazdutide monotherapy in treatment-naive T2D patients. DREAMS-2 compared mazdutide versus dulaglutide in T2D patients with inadequate glycemic control on oral antidiabetics. Both met their primary endpoints. DREAMS-2 demonstrated superiority to dulaglutide in both glucose lowering and weight reduction.
DREAMS-3 (head-to-head versus semaglutide in Chinese T2D patients with obesity): 48% of mazdutide participants achieved the combined endpoint of HbA1c below 7% plus at least 10% body weight loss, versus 21% of semaglutide 1.0 mg participants (p less than 0.0001).
China approved mazdutide for glycemic control in adults with T2D in September 2025, covering both monotherapy and add-on to oral antidiabetics.
The T2D evidence base is robust within Chinese populations, with Phase 3 data showing superiority to dulaglutide and compelling dual-benefit data versus semaglutide 1.0 mg. The 9 mg dose has not been formally approved in T2D yet. As with all mazdutide data, the exclusively Chinese population context requires qualification.
The liver fat reduction data from GLORY-1 are striking. In participants with baseline liver fat content of at least 10% by MRI-PDFF, the mean percentage change in liver fat from baseline was minus 65.85% with mazdutide 4 mg, minus 80.24% with mazdutide 6 mg, and minus 5.27% with placebo.
In GLORY-2 (9 mg, 60 weeks), liver fat reduction in participants with baseline liver fat at least 10% was 71.9% versus 5.1% with placebo.
The Phase 2 MASH trial initiated in July 2025 is the first dedicated investigation of mazdutide as a treatment for MASH. No results are yet available.
The liver fat reduction data are among the most compelling secondary findings in the mazdutide program. The 80% reduction in MRI-PDFF is biologically plausible via the glucagon receptor mechanism. However, these are exploratory analyses from obesity trials, not primary MASH outcomes trials. Reduction in liver fat content does not automatically translate to reduction in fibrosis or MASH-specific clinical endpoints.
The Phase 1 high-dose trial represents the first published data with substantial Western population participation. At 20 weeks with the 16 mg dose, mean percent change from baseline was minus 20.0% (Cohort 1) and minus 21.0% (Cohort 2) versus minus 0.1% with placebo (p less than 0.001). No serious adverse events. The notable finding was elevated heart rate: 91.7% of mazdutide participants had pulse rate increase of at least 10 bpm on two consecutive visits, compared with 37.5% of placebo.
Eli Lilly's US Phase 2 obesity trial has enrolled 179 participants and is expected to read out imminently as of early 2026. No results have been published. These data will be the first formal evidence in a US-enrolled population at the doses being pursued for registration.
The Phase 1 high-dose data in a predominantly Western cohort are directionally positive (20% weight loss at 20 weeks), but the trial is small (n=32) and tests a dose (16 mg) that is twice the highest Phase 3-tested dose. The heart rate elevation at 16 mg deserves monitoring. The US Phase 2 result (n=179) will determine whether Eli Lilly proceeds to Phase 3 registration trials in the US.
Phase 3 trials tested 3-9mg for obesity.
Mazdutide is not FDA-approved and not compoundable in the US under current law. It is marketed in China as Xinermei by Innovent Biologics at 4 mg and 6 mg doses. The 9 mg dose is under NDA review at NMPA. Any doses above 6 mg are not currently approved anywhere. Heart rate elevation (greater than 10 bpm increase) was observed in 91.7% of participants at 16 mg in Phase 1, a dose-dependent effect. At 4 to 6 mg Phase 3 doses, mean heart rate increase was 2.6 bpm. Research chemical vendors sourcing product labeled as mazdutide are providing a compound without any Western regulatory framework or quality standards.
Among GLP-1-based obesity treatments, semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for weight management; retatrutide (Eli Lilly's GIP/GLP-1/glucagon triple agonist) is in Phase 3 with results pending; cagrilintide (NDA filed) awaits an FDA decision. Mazdutide is the only drug in this series to have received regulatory approval somewhere, giving it a higher evidence tier than typical research peptides, but that approval is China-specific. Within the GLP-1/glucagon dual agonist class, survodutide (Boehringer Ingelheim) is also in Phase 3 globally. The glucagon receptor component is mazdutide's mechanistic differentiator from tirzepatide (which uses GIP rather than glucagon as the second receptor target). Retatrutide includes glucagon as its third target, making it a triple agonist with a larger mechanistic overlap with mazdutide than tirzepatide has.
The safety profile of mazdutide across its clinical development program is broadly consistent with the GLP-1 receptor agonist class, with additional signals related to glucagon receptor activation.
Gastrointestinal adverse events are the dominant signal. In GLORY-1, nausea, diarrhea, and vomiting were the most frequently reported adverse events, predominantly mild to moderate in severity. Adverse event-related discontinuation was remarkably low: 1.5% at 4 mg, 0.5% at 6 mg, and 1.0% with placebo. This is substantially lower than rates typically reported for semaglutide (4% to 7%) and tirzepatide (10% to 30% at higher doses). At the 9 mg dose, nausea occurred in 50.0% of mazdutide participants versus 0% with placebo, and vomiting in 36.7% versus 10.0%.
Heart rate elevation: in the high-dose Phase 1 trial (16 mg target), 91.7% of mazdutide participants had a pulse rate increase of at least 10 bpm on two consecutive visits, compared with 37.5% of placebo participants. In GLORY-1 at the Phase 3 doses (4 mg and 6 mg), mean heart rate change was 2.6 bpm, which is not clinically meaningful. The divergence suggests a dose-dependent heart rate effect with implications for the 9 mg dose and patients with pre-existing cardiovascular conditions.
Blood beta-hydroxybutyrate increased in the high-dose Phase 1 trial, consistent with glucagon-receptor-mediated fatty acid oxidation and ketogenesis. Liver enzymes were reduced, not elevated, consistent with the dramatic liver fat reductions.
Hypoglycemia risk in non-diabetic patients was not elevated compared to placebo. In T2D patients on insulin or sulfonylureas, standard precautions apply.
Cardiovascular outcome data do not yet exist. No cardiovascular outcomes trial for mazdutide has been completed.
Mazdutide is the world's first approved dual GCG/GLP-1 receptor agonist, a class distinction that is real and scientifically meaningful. The Phase 3 data published in the NEJM and Nature are methodologically sound. The 14% weight loss at 6 mg, the low discontinuation rate (0.5% in GLORY-1), and the dramatic liver fat reductions (80% at 6 mg) are genuine findings in well-conducted trials.
The honest constraint is the population boundary. Every Phase 3 trial was run in Chinese adults, at lower weights, using Chinese BMI thresholds. Harvard and CU editorialists who accompanied the NEJM publication specifically called this out. The US Phase 2 data (n=179, pending) will be the first real test of whether these results translate.
For readers in China, where mazdutide is now marketed as Xinermei at 4 mg and 6 mg: this is a first-in-class approved drug with the data to justify its use. For readers everywhere else: the evidence is promising, the mechanism is compelling, and the compound will almost certainly enter Western Phase 3 development with Eli Lilly in the coming years, but no FDA approval exists, no Western Phase 3 is complete, and any product purchased from research chemical vendors operates entirely outside any regulatory framework.
The glucagon receptor component is what makes this mechanistically interesting beyond standard GLP-1 agonism. Whether that translates to meaningfully superior efficacy in Western populations at comparable doses remains the unanswered question of the next 3 to 4 years of mazdutide's development.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use